Released Jan 29, 2020, after the close
10-K filed Jan 29, 2020, 90 days after period end · 0001654954-20-000889
Q4 2019 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.82M$4.82M derived−15.0% vs Q4 2018−2.9% vs Q3 2019
Net Income$477.60K$477.60K derived−85.7% vs Q4 2018+10.8% vs Q3 2019
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$1,538,230−17.9%
Operating Incomederived$388,039−22.0%
Operating Cash Flowderived-$539,810N/M
Free Cash Flowderived-$548,943N/M
Margins · derived
Gross margin31.9%−1.1 pt vs Q4 2018
Operating margin8.0%−0.7 pt vs Q4 2018
Net margin9.9%−49.0 pt vs Q4 2018
What the release said
The release
Same quarter
| Metric | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $4.82M | $5.67M | — | — |
| Net Income | $477.60K | $3.34M | -$547.03K | -$513.32K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR